menu
    • menu
    [{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Therapeutics Announces Presentations at ASGCT and ARVO Annual Meetings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2-ND4","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"rAAV2-ND4","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Aavnergene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Partnership","leadProduct":"AAV capsids-gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Neurophth Therapeutics \/ Neurophth","highestDevelopmentStatusID":"3","companyTruncated":"Neurophth Therapeutics \/ Neurophth"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"NR082","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurophth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"CMG-SDIC Capital","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Series C Financing","leadProduct":"rAAV-ND4","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neurophth Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Neurophth Therapeutics \/ CMG-SDIC Capital","highestDevelopmentStatusID":"5","companyTruncated":"Neurophth Therapeutics \/ CMG-SDIC Capital"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"NR082","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurophth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV2-ND4","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"rAAV2-ND1","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Neurophth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"NR082","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurophth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Yangtze River-CMB International Industry Fund","pharmaFlowCategory":"D","amount":"$95.0 million","upfrontCash":"Undisclosed","newsHeadline":"Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Series C Financing","leadProduct":"Esonadogene Imvoparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Neurophth Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurophth Therapeutics \/ Yangtze River-CMB International Industry Fund","highestDevelopmentStatusID":"9","companyTruncated":"Neurophth Therapeutics \/ Yangtze River-CMB International Industry Fund"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Announces First Patient Dosed in Phase I\/II Clinical Trial of Second Gene Therapy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"NFS-02","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurophth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Announces Completion of Patient Enrollment for Opvika\u00ae Phase I\/II Clinical Trial in the U.S.","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Esonadogene Imvoparvovec","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurophth Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neurophth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurophth Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Neurophth Therapeutics

    Menu

    Neurophth Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esonadogene Imvoparvovec

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.

                            Details : Opvika (Esonadogene Imvoparvovec) is a MT-ND4 modulator. It is being evaluated for the treatment of Leber hereditary optic neuropathy caused by ND4 mutation (ND4-LHON).

                            Brand Name : Opvika

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 19, 2024

                            Lead Product(s) : Esonadogene Imvoparvovec

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NFS-02

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy

                            Details : NFS-02 is Neurophth’s second gene therapy, currently evaluating in multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary optic neuropathy caused by ND1 mutation.

                            Brand Name : NFS-02

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 17, 2023

                            Lead Product(s) : NFS-02

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esonadogene Imvoparvovec

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II/ Phase III

                            Sponsor : Yangtze River-CMB International Industry Fund

                            Deal Size : $95.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials

                            Details : The net proceeds will advance clinical trials for Neurophth's core products, enhancing the firm's R&D capabilities and expanding its pipeline, including NFS-01 (esonadogene imvoparvovec), a rAAV2-ND4 gene therapy being developed to treat Leber's heredita...

                            Brand Name : NFS-01

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 11, 2023

                            Lead Product(s) : Esonadogene Imvoparvovec

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Yangtze River-CMB International Industry Fund

                            Deal Size : $95.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NR082

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinica...

                            Details : NR082 (rAAV2-ND4), a novel recombinant AAV2, containing a mitochondria codon-optimized NADH-dehydrogenase subunit 4 gene which delivers the correct genes to the patients' damaged optic ganglion cells. It is being developed for LHON associated with mtND4 ...

                            Brand Name : NR082

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 22, 2023

                            Lead Product(s) : NR082

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rAAV2-ND1

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON

                            Details : Investigational NFS-02, a novel recombinant adeno-associated viral serotype 2 vector (rAAV2) containing a codon-optimized of NADH-dehydrogenase subunit 1 gene, is a novel ophthalmic injection that is being developed for the treatment of Leber hereditary ...

                            Brand Name : NFS-02

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            December 19, 2022

                            Lead Product(s) : rAAV2-ND1

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rAAV2-ND4

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON

                            Details : NR082 (rAAV2-ND4), a recombinant adeno-associated viral vector, serotype 2, containing human ND4 codon-optimized gene under the control of the cytomegalovirus promoter and enhancer, is a novel gene therapy.

                            Brand Name : NR082

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 15, 2022

                            Lead Product(s) : rAAV2-ND4

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NR082

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 ...

                            Details : INDA Clearance received from USFDA for NFS-01 (NR082), a novel recombinant adeno-associated viral serotype 2 on the basis of results from three investigator-initiated trials which demonstrated favorable results in patients LHON associated ND4 mutation.

                            Brand Name : NFS-01

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 18, 2022

                            Lead Product(s) : NR082

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rAAV-ND4

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : CMG-SDIC Capital

                            Deal Size : $60.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies

                            Details : The financing will be used to progress its lead clinical program in LHON to ex-China, enrich R&D pipeline and programs through business development and continue to expand the international standard gene therapy manufacturing platform.

                            Brand Name : NFS-01

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 22, 2021

                            Lead Product(s) : rAAV-ND4

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : CMG-SDIC Capital

                            Deal Size : $60.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NR082

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy

                            Details : NR082, a novel recombinant adeno-associated viral serotype 2 containing a codon-optimized of ND4 gene under the control of the cytomegalovirus promoter and enhancer, is a novel ophthalmic injection that is being developed for the treatment of LHON in ND4...

                            Brand Name : NFS-01

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 01, 2021

                            Lead Product(s) : NR082

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed

                            Neurophth Therapeutics

                            China arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV capsids-gene therapy

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Recipient : Aavnergene

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy

                            Details : Subject to the terms of the agreement, Neurophth will make an initial cash payment to AAVnerGene to test ~100 AAV capsids. Within 6-12 months upon receiving the AAV capsids, Neurophth is responsible for completing the preclinical studies on these capsids...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 19, 2021

                            Lead Product(s) : AAV capsids-gene therapy

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Recipient : Aavnergene

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth